{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:59:55Z","timestamp":1792040395880,"version":"4.4.0"},"reference-count":57,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Stiftung Oskar-Helene-Heim"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: We aimed to assess medication risks and determine factors influencing the health-related quality of life (HRQOL) in cancer inpatients. Methods: A retrospective analysis was conducted to identify drug-related problems (DRPs) based on medication reviews, including patient-reported outcomes (PROs). Multiple linear regression analyses were performed to identify sociodemographic, disease-related, and drug therapy-related factors influencing changes from hospital admission to discharge in the scales of the EORTC QLQ-C30 questionnaire. Results: A total of 162 inpatients with various hematological and solid cancer diseases was analyzed. Patients received a mean of 11.6 drugs and 92.6% of patients exhibited polymedication resulting in a mean of 4.0 DRPs per patient. Based on PRO data, 21.5% of DRPs were identified. Multiple linear regression models described the variance of the changes in global HRQOL and physical function in a weak-to-moderate way. While drug therapy-related factors had no influence, relapse status and duration of hospital stay were identified as significant covariates for global HRQOL and physical function, respectively. Conclusion: This analysis describes underlying DRPs in a German cancer inpatient population. PROs provided valuable information for performing medication reviews. The multiple linear regression models for global HRQOL and physical function provided explanations for changes during hospital stay.<\/jats:p>","DOI":"10.3390\/cancers16112110","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T11:43:48Z","timestamp":1717155828000},"page":"2110","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Medication Risks and Their Association with Patient-Reported Outcomes in Inpatients with Cancer"],"prefix":"10.3390","volume":"16","author":[{"given":"Maximilian","family":"G\u00fcnther","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0764-1049","authenticated-orcid":false,"given":"Markus","family":"Schuler","sequence":"additional","affiliation":[{"name":"Onkologischer Schwerpunkt am Oskar-Helene-Heim, 14195 Berlin, Germany"},{"name":"Division of Hematology, Oncology and Stem Cell Transplantation, Medical Clinic I, Department of Medicine I, University Hospital Carl Gustav Carus, Technical University of Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leopold","family":"Hentschel","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Stem Cell Transplantation, Medical Clinic I, Department of Medicine I, University Hospital Carl Gustav Carus, Technical University of Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Salm","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Innere Medizin C, Universit\u00e4tsmedizin Greifswald, 17489 Greifswald, Germany"},{"name":"Sarcoma Center Berlin-Brandenburg, Helios Hospital Bad Saarow, 15526 Bad Saarow, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Therese","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry, Informatics and Epidemiology, Medical Faculty, University of Bonn, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Jaehde","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jgo.2015.12.002","article-title":"Comorbidity in older adults with cancer","volume":"7","author":"Williams","year":"2016","journal-title":"J. Geriatr. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/bjc.2012.46","article-title":"Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality","volume":"106","author":"Hallas","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00520-014-2171-x","article-title":"Prevalence and factors associated with polypharmacy in older people with cancer","volume":"22","author":"Turner","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00520-015-2970-8","article-title":"Polypharmacy cut-points in older people with cancer: How many medications are too many?","volume":"24","author":"Turner","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/clpt.2011.258","article-title":"High-Risk Prescribing and Incidence of Frailty Among Older Community-Dwelling Men","volume":"91","author":"Gnjidic","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jgo.2017.04.005","article-title":"Implementing a pharmacist-led, individualized medication assessment and planning (iMAP) intervention to reduce medication related problems among older adults with cancer","volume":"8","author":"Nightingale","year":"2017","journal-title":"J. Geriatr. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jgo.2012.02.005","article-title":"Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer","volume":"3","author":"Prithviraj","year":"2012","journal-title":"J. Geriatr. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jgo.2016.07.010","article-title":"Polypharmacy and potentially inappropriate medication use in geriatric oncology","volume":"7","author":"Sharma","year":"2016","journal-title":"J. Geriatr. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ortland, I., Ott, M.M., Kowar, M., Sippel, C., Ko, Y.-D., Jacobs, A.H., and Jaehde, U. (2022). Medication risks in older patients (70+) with cancer and their association with therapy-related toxicity. BMC Geriatr., 22.","DOI":"10.1186\/s12877-022-03390-z"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jgo.2021.02.021","article-title":"Potentially inappropriate medication (PIM) use and severe drug interactions (SDIs) in older adults with cancer","volume":"12","author":"Lavan","year":"2021","journal-title":"J. Geriatr. Oncol."},{"key":"ref_11","first-page":"211","article-title":"The impact of polypharmacy on patient outcomes in older adults with cancer","volume":"23","author":"Nightingale","year":"2017","journal-title":"Cancer J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11912-017-0632-3","article-title":"Polypharmacy in the Geriatric Oncology Population","volume":"19","author":"Hersh","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"vii36","DOI":"10.1093\/annonc\/mdt266","article-title":"Polypharmacy and the management of the older cancer patient","volume":"24","author":"Balducci","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/gerona\/glaa128","article-title":"Systematic Review and Meta-Analysis on the Associations of Polypharmacy and Potentially Inappropriate Medication with Adverse Outcomes in Older Cancer Patients","volume":"76","author":"Chen","year":"2021","journal-title":"J. Gerontol. Ser. A"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jgo.2015.05.001","article-title":"Drug-related problems in elderly patients with cancer receiving outpatient chemotherapy","volume":"6","author":"Yeoh","year":"2015","journal-title":"J. Geriatr. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/10781552241229662","article-title":"Drug-related problems in cancer patients: A systematic review","volume":"30","author":"Jayalakshmi","year":"2024","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_17","unstructured":"(2020). PCNE Classification for Drug-Related Problems, Pharmaceutical Care Network Europe (PCNE). Available online: https:\/\/www.pcne.org."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0897190013504954","article-title":"Outcomes Assessment of a Pharmacist-Directed Seamless Care Program in an Ambulatory Oncology Clinic","volume":"27","author":"Edwards","year":"2014","journal-title":"J. Pharm. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1177\/1078155220962178","article-title":"Drug-related problems in head and neck cancer patients identified by repeated medication reviews on consecutive therapy cycles","volume":"27","author":"Vucur","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/1078155220964539","article-title":"Acceptability of pharmacist-led interventions to resolve drug-related problems in patients with chronic myeloid leukaemia","volume":"27","author":"Tan","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00520-014-2160-0","article-title":"Characteristics of unplanned hospital admissions due to drug-related problems in cancer patients","volume":"22","author":"Chan","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1007\/s00520-020-05916-w","article-title":"Drug-related problems and risk factors related to unplanned hospital readmission among cancer patients in Belgium","volume":"29","author":"Koubaity","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1078155212465995","article-title":"Adverse drug events resulting in admission to the intensive care unit in oncology patients: Incidence, characteristics and associated cost","volume":"19","author":"Nazer","year":"2013","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_24","unstructured":"(2014). Grundsatzpapier zur Medikationsanalyse und zum Medikationsmanagement, Bundesvereinigung Deutscher Apothekerverb\u00e4nde e. V. (ABDA). Available online: https:\/\/www.abda.de."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/jcpt.12562","article-title":"The effects of pharmacist interventions on adult outpatients with cancer: A systematic review","volume":"42","author":"Colombo","year":"2017","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/1078155218783814","article-title":"A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies","volume":"25","author":"Maleki","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.sapharm.2024.02.006","article-title":"Impact of pharmacist-led interventions on medication-related problems among patients treated for cancer: A systematic review and meta-analysis of randomized control trials","volume":"20","author":"Fentie","year":"2024","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1007\/s00432-023-04630-4","article-title":"Clinical and economic impact of clinical oncology pharmacy in cancer patients receiving injectable anticancer treatments: A systematic review","volume":"149","author":"Lattard","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s11096-020-00992-8","article-title":"Significance of a clinical pharmacist-led comprehensive medication management program for hospitalized oncology patients","volume":"42","author":"Umar","year":"2020","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1477-7525-7-102","article-title":"Quality of life data as prognostic indicators of survival in cancer patients: An overview of the literature from 1982 to 2008","volume":"7","author":"Montazeri","year":"2009","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00520-017-3865-7","article-title":"Patient-reported outcome use in oncology: A systematic review of the impact on patient-clinician communication","volume":"26","author":"Yang","year":"2018","journal-title":"Support. Care Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2013.53.5948","article-title":"What Is the Value of the Routine Use of Patient-Reported Outcome Measures toward Improvement of Patient Outcomes, Processes of Care, and Health Service Outcomes in Cancer Care? A Systematic Review of Controlled Trials","volume":"32","author":"Kotronoulas","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/JCO.2004.06.078","article-title":"Measuring Quality of Life in Routine Oncology Practice Improves Communication and Patient Well-Being: A Randomized Controlled Trial","volume":"22","author":"Velikova","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/EDBK_200383","article-title":"Implementation of Patient-Reported Outcomes in Routine Medical Care","volume":"38","author":"Basch","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom Monitoring with Patient-Reported Outcomes during Routine Cancer Treatment: A Randomized Controlled Trial","volume":"34","author":"Basch","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00520-023-08014-9","article-title":"Evaluation of electronic patient\u2013reported outcome assessment in inpatient cancer care: A feasibility study","volume":"31","author":"Salm","year":"2023","journal-title":"Support. Care Cancer"},{"key":"ref_38","unstructured":"(2016). Richtlinie (EU) 2016\/680 des Europ\u00e4ischen Parlaments und des Rates vom 27 April 2016 zum Schutz nat\u00fcrlicher Personen bei der Verarbeitung Personenbezogener Daten durch die zust\u00e4ndigen Beh\u00f6rden zum Zwecke der Verh\u00fctung, Ermittlung, Aufdeckung oder Verfolgung von Straftaten oder der Strafvollstreckung sowie zum freien Datenverkehr und zur Aufhebung des Rahmenbeschlusses 2008\/977\/JI des Rates, Europ\u00e4isches Parlament und Rat der Europ\u00e4ischen Union. Available online: https:\/\/eur-lex.europa.eu\/homepage.html."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_40","unstructured":"(2024, May 20). Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), Available online: https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejon.2014.07.007","article-title":"Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Kirsch","year":"2015","journal-title":"Eur. J. Oncol. Nurs."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/annonc\/mdw422","article-title":"Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE\u2122)","volume":"27","author":"Hagelstein","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_43","unstructured":"Fayers, P.M., Aaronson, N.K., Bjordal, K., Groenvold, M., Curran, D., and Bottomley, A. (2001). The EORTC QLQ-C30 Scoring Manual, European Organisation for Research and Treatment of Cancer. [3rd ed.]."},{"key":"ref_44","unstructured":"European Organisation for Research and Treatment of Cancer (2024, May 20). EORTC Quality of Life Questionnaires. Available online: https:\/\/qol.eortc.org\/questionnaires."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_46","unstructured":"(2016). Position Paper on PCNE Medication Review, Pharmaceutical Care Network Europe (PCNE)."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11096-017-0442-6","article-title":"Documentation of pharmaceutical care: Development of an intervention oriented classification system","volume":"39","author":"Maes","year":"2017","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Bortz, J., and Schuster, C. (2010). Statistik f\u00fcr Human- und Sozialwissenschaftler, Springer. [7th ed.].","DOI":"10.1007\/978-3-642-12770-0"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Wei\u00df, C. (2019). Basiswissen Medizinische Statistik, Springer. [7th ed.].","DOI":"10.1007\/978-3-662-56588-9"},{"key":"ref_50","unstructured":"Cohen, J. (1988). Statistical Power Analysis for the Behavioral Sciences, Erlbaum Associates. [2nd ed.]."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00520-010-1016-5","article-title":"Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials","volume":"19","author":"Maringwa","year":"2011","journal-title":"Support. Care Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/ajco.12070","article-title":"Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer","volume":"10","author":"Bedard","year":"2014","journal-title":"Asia-Pacific J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1111\/codi.15295","article-title":"Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy","volume":"22","author":"Musoro","year":"2020","journal-title":"Color. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00439229","article-title":"The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30","volume":"5","author":"King","year":"1996","journal-title":"Qual. Life Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0168-8510(00)00138-X","article-title":"What is \u2018best practice\u2019 in health care? State of the art and perspectives in improving the effectiveness and efficiency of the European health care systems","volume":"56","author":"Perleth","year":"2001","journal-title":"Health Policy"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/bmj.321.7262.694","article-title":"Framework for design and evaluation of complex interventions to improve health","volume":"321","author":"Campbell","year":"2000","journal-title":"BMJ"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/11\/2110\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:51:57Z","timestamp":1760107917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/11\/2110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":57,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["cancers16112110"],"URL":"https:\/\/doi.org\/10.3390\/cancers16112110","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]}}}